The cannabinoid CB1 receptor antagonists rimonabant (SR141716) and AM251 directly potentiate GABAA receptors
نویسندگان
چکیده
منابع مشابه
P 9: Neuoprotective Effect of Cannabinoid CB1 Receptor Antagonists Rimonabant and AM251 on Hypoxic Mouse Model of Brain Oxidative Stress
Introduction: The hypoxic state, in which experimental animals were subjected to an atmosphere of 5% O2 and %95 N2, has been used to screen agents for possible cerebral protection by measuring their ability to prolong survival time in mice exposed to hypoxia. Researchers showed that rimonabant and AM251 allosteric potentiate all but the β1 subunit containing GABAA receptors at nM...
متن کاملThe cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism.
The endocannabinoid system has been shown to modulate key cell-signaling pathways involved in cancer cell growth. In this study, we show that cannabinoid receptor type 1 (CB1) antagonist Rimonabant (SR141716) inhibited human breast cancer cell proliferation, being more effective in highly invasive metastatic MDA-MB-231 cells than in less-invasive T47D and MCF-7 cells. The SR141716 antiprolifera...
متن کاملCannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.
BACKGROUND Rimonabant is a selective type 1 cannabinoid (CB1) receptor antagonist. It may assist with smoking cessation by restoring the balance of the endocannabinoid system, which can be disrupted by prolonged use of nicotine. Rimonabant also seeks to address many smokers' reluctance to persist with a quit attempt because of concerns about weight gain. OBJECTIVES To determine whether select...
متن کاملBioisosteric replacement of the pyrazole 3-carboxamide moiety of rimonabant. A novel series of oxadiazoles as CB1 cannabinoid receptor antagonists.
Based on the bioisosteric replacement of the pyrazole C3-carboxamide of rimonabant with a 5-alkyl oxadiazole ring, a novel class of oxadiazole derivatives with promising biological activity towards CB1 receptors was discovered. Among them, compounds with an alkyl linker containing a strong electron-withdrawing group (e.g., CF(3)) and a sterically favorable bulky group (e.g., t-butyl) exhibited ...
متن کاملPM288. Preclinical Evaluation of Neutral Cannabinoid CB1 Receptor Antagonists and Cannabinoid CB1 Receptor Negative Allosteric Modulators for Treating Drug Addiction
s | 3 of adverse effects that currently limit the use of opioids in the clinic. Supported by USPHS Grant K05DA017918 PM288 Preclinical Evaluation of Neutral Cannabinoid CB1 Receptor Antagonists and Cannabinoid CB1 Receptor Negative Allosteric Modulators for Treating Drug Addiction Eliot L. Gardner1, Guo-Hua Bi1, Ganesh Thakur2, Alexandros Makriyannis2, Herbert H. Seltzman3, Xiang-Hu He4, Zheng-...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Pharmacology
سال: 2012
ISSN: 0007-1188
DOI: 10.1111/j.1476-5381.2011.01405.x